Australia Biopsy Devices Market Anticipated to Reach US$ 94.3 Million during 2026-2034

Australia Biopsy Devices Market Overview

According to IMARC Group's latest research report, the Australia biopsy devices market reached a value of USD 59.1 Million in 2025. Looking forward, the market is expected to reach USD 94.3 Million by 2034, growing at a CAGR of 5.32% during 2026-2034. The market is driven by an estimated 169,759 new cancer cases diagnosed nationally in 2025, the launch of Australia's National Lung Cancer Screening Programme in July 2025, TGA approval of AI-driven biopsy navigation platforms like LungVision in March 2025, total health system cancer expenditure reaching AUD 19.7 billion as the most expensive disease group, and the federal government's AUD 150.3 million investment in precision oncology and rare cancer programs.

Get a sample copy of this report: https://www.imarcgroup.com/australia-biopsy-devices-market/requestsample

Australia Biopsy Devices Market Summary

• Australia's rising cancer burden is the primary demand driver for biopsy devices, with an estimated 169,759 new cancer cases projected for 2025, including approximately 94,956 in males and 74,803 in females. The crude cancer incidence rate has climbed to 614 cases per 100,000 persons, up from 463 cases per 100,000 in 2000. Breast cancer remains the most commonly diagnosed cancer in females with approximately 20,000 cases annually, prostate cancer leads male diagnoses at 25,500 cases, and lung cancer accounts for the highest number of cancer-related deaths at approximately 8,900 per year. Each of these cancer types requires tissue biopsy as an essential step in the diagnostic pathway.

• Needle biopsy procedures are gaining significant ground over traditional surgical biopsies across Australian healthcare facilities, driven by their advantages of reduced patient discomfort, faster recovery, fewer complications, and lower procedural costs. Core needle biopsy (CNB) and fine needle aspiration biopsy (FNAB) techniques provide high-accuracy tissue sampling through minimally invasive approaches that can often be performed as outpatient procedures. This shift aligns with broader healthcare system objectives of improving patient throughput, reducing hospital bed utilization, and delivering cost-effective diagnostic services.

• Image-guided biopsy technologies are transforming diagnostic accuracy in Australian oncology practice, with ultrasound-guided, MRI-guided, and stereotactic-guided procedures providing real-time visualization that enables clinicians to target suspicious tissue with unprecedented precision. MRI-ultrasound fusion technology is experiencing particularly strong growth in prostate biopsy applications, improving detection rates for clinically significant cancers while reducing unnecessary biopsies. These integrated imaging-biopsy systems minimize sampling errors, improve diagnostic yields, and are increasingly considered the standard of care in tertiary cancer centers.

• Breast biopsy represents one of the highest-volume application segments, supported by Australia's national BreastScreen program and the approximately 20,000 new breast cancer cases diagnosed in females annually. Five-year relative survival rates for breast cancer have improved dramatically from 78% in the early 1990s to 93% currently, partly attributable to advances in image-guided biopsy techniques that enable earlier and more accurate diagnosis. The adoption of vacuum-assisted biopsy devices and stereotactic-guided breast biopsy systems continues to expand across both metropolitan and regional breast screening services.

• Lung biopsy is emerging as a particularly dynamic application segment, catalyzed by the launch of Australia's National Lung Cancer Screening Programme (NLCSP) in July 2025. The program uses low-dose CT scans to screen high-risk individuals aged 50 to 70 with significant smoking histories, and positive screening results drive referrals for diagnostic biopsy procedures. The adoption of robotic bronchoscopy platforms, such as the Ion system deployed at Epworth Eastern in Melbourne achieving diagnostic yields up to 90% for challenging pulmonary nodules, is transforming lung biopsy accuracy and accessibility.

• Australia's total health expenditure reached AUD 270.5 billion in 2023-24, representing 10% of GDP, with cancer being the most expensive disease group at AUD 19.7 billion. This spending has doubled since 2013-14, reflecting both the growing cancer burden and increasing investment in advanced diagnostic and treatment infrastructure. The 2025 federal budget allocated AUD 150.3 million to extend precision oncology programs including the Zero Childhood Cancer Program (ZERO), the Precision Oncology Screening Platform (PrOSPeCT), and the Australian Rare Cancers Portal, along with AUD 77 million for a statewide cancer network.

• Hospitals and clinics serve as the dominant end-user segment, housing the imaging infrastructure, procedural suites, and specialist expertise required for complex biopsy procedures. Australia's public hospital system, bolstered by a AUD 1.8 billion one-off funding boost in the 2025 federal budget, provides the foundational infrastructure for high-volume biopsy services. Private hospitals and specialist diagnostic centers complement this capacity, with facilities like Epworth Eastern leading the adoption of next-generation technologies including robotic bronchoscopy and AI-assisted biopsy navigation systems.

• The ACT and New South Wales region commands the largest share of the biopsy devices market, reflecting the concentration of major cancer treatment centers, research hospitals, and specialist diagnostic facilities in Sydney and Canberra. Victoria and Tasmania follow closely, anchored by Melbourne's world-class oncology institutions including the Peter MacCallum Cancer Centre. Queensland's growing population and expanding healthcare infrastructure, along with Western Australia's investment in regional cancer diagnostic services, contribute to geographically distributed demand for advanced biopsy equipment.

Key Trends Shaping the Australia Biopsy Devices Market

• AI-powered biopsy navigation and diagnostic systems are rapidly entering the Australian market, with LungVision from Body Vision Medical receiving TGA regulatory approval in March 2025. This AI-driven imaging system transforms standard C-arm fluoroscopy into a 3D imaging platform, enabling real-time navigation during bronchoscopic biopsies. In New South Wales, AI-driven machine reading technology in breast screening is projected to reduce the number of women recalled for additional diagnostic procedures, including needle biopsies, by approximately 20%, improving screening efficiency while reducing patient anxiety and healthcare costs.

• Robotic-assisted biopsy platforms are establishing a foothold in Australian healthcare, with Epworth Eastern in Melbourne becoming the first private hospital to deploy the next-generation Ion robotic bronchoscope in September 2025. The system uses built-in shape-sensing navigation to access pulmonary nodules previously unreachable with conventional bronchoscopes, achieving diagnostic yields in the 80 to 90% range even for lesions under 20mm. This technology is particularly relevant as the new National Lung Cancer Screening Programme generates increased demand for confirmatory biopsy procedures.

• Liquid biopsy technology is emerging as a complementary diagnostic approach, with La Trobe University announcing a breakthrough in detecting early esophageal cancer through a liquid biopsy test in October 2024. These blood-based or fluid-based tests analyze circulating tumor DNA, circulating tumor cells, or other biomarkers to detect cancer without requiring tissue sampling. While not replacing traditional tissue biopsies entirely, liquid biopsy offers promise for screening, monitoring treatment response, and detecting recurrence with significantly less patient burden.

• The convergence of optical biopsy and telepathology is creating new diagnostic paradigms, with Optiscan Imaging featured as a leader in optical biopsy innovation through devices for breast surgery and a telepathology platform aimed at improving real-time cancer diagnosis and surgical accuracy. In November 2024, Optiscan partnered with Monash University to develop AI-powered endoscopes for real-time cancer detection during gastrointestinal procedures, supported by an Australian government CRC-P grant, targeting reduced screening times and improved diagnostic accuracy.

• Personalized precision oncology is driving demand for advanced biopsy techniques that yield not just diagnostic confirmation but molecular and genomic information for treatment selection. The federal government's AUD 150.3 million investment in programs like PrOSPeCT and ZERO reflects the growing clinical need for high-quality tissue samples that can undergo comprehensive genomic profiling. This trend favors core needle biopsy over fine needle aspiration and is increasing demand for biopsy devices capable of extracting larger tissue volumes while maintaining minimally invasive procedural profiles.

Explore the full report with TOC & list of figures: https://www.imarcgroup.com/australia-biopsy-devices-market

Market Growth Factors

Rising Cancer Incidence and National Screening Program Expansion

Australia's growing cancer burden represents the most fundamental demand driver for biopsy devices, with an estimated 169,759 new cancer cases projected for 2025 at an incidence rate of 614 per 100,000 persons. Breast cancer (approximately 20,000 female cases annually), prostate cancer (25,500 cases), and lung cancer (the leading cause of cancer death at 8,900 fatalities per year) each require tissue biopsy as an essential diagnostic step. The launch of the National Lung Cancer Screening Programme in July 2025, targeting high-risk individuals aged 50 to 70 with low-dose CT scans, is expected to significantly increase the volume of lung biopsy referrals as suspicious nodules are identified through screening. Similarly, the established BreastScreen Australia and National Bowel Cancer Screening programs continue to generate sustained demand for breast and colorectal biopsy procedures. Five-year survival rates for breast cancer have risen to 93% and prostate cancer to 96%, partly driven by improvements in early detection through advanced biopsy technologies, reinforcing the clinical and economic case for continued investment in screening and diagnostic capacity.

Technological Innovation in Minimally Invasive and Image-Guided Procedures

Rapid advances in biopsy technology are expanding procedural capabilities while improving patient outcomes, creating a technology-driven growth cycle in the Australian market. The TGA approval of LungVision's AI-driven 3D imaging navigation system in March 2025 and the deployment of the Ion robotic bronchoscope at Epworth Eastern in September 2025 demonstrate the pace of innovation reaching Australian clinical practice. These systems achieve diagnostic yields of 80 to 90% for challenging pulmonary nodules that were previously difficult to access with conventional techniques. MRI-ultrasound fusion technology is similarly advancing prostate biopsy accuracy, while vacuum-assisted devices and stereotactic guidance systems continue to refine breast biopsy precision. The integration of AI with conventional imaging modalities is enhancing biopsy targeting accuracy across all application areas. In NSW, AI-assisted breast screening analysis is expected to reduce unnecessary recall rates by approximately 20%, optimizing the diagnostic pathway and directing biopsy resources toward patients who most need them. These technological capabilities are driving both replacement purchases at established facilities and greenfield installations at expanding healthcare centers.

Healthcare Investment and Precision Oncology Infrastructure

Australia's sustained investment in healthcare infrastructure and precision oncology programs provides a robust funding foundation for biopsy device adoption. Total health system expenditure reached AUD 270.5 billion in 2023-24, representing 10% of GDP, with cancer as the most expensive disease group at AUD 19.7 billion, a figure that has doubled since 2013-14. The 2025 federal budget delivered a AUD 1.8 billion one-off boost for public hospitals and AUD 150.3 million specifically for precision oncology programs including the Zero Childhood Cancer Program, the Precision Oncology Screening Platform (PrOSPeCT), and the Australian Rare Cancers Portal. An additional AUD 77 million was allocated for establishing a statewide cancer network to maximize prevention, early detection, and treatment delivery. This institutional investment supports the procurement of advanced biopsy guidance systems, needle-based devices, and integrated imaging platforms across both public and private hospital settings. The growing emphasis on precision medicine, which requires high-quality tissue samples for genomic profiling, further elevates demand for sophisticated biopsy devices that can deliver adequate specimen volumes through minimally invasive approaches.

Australia Biopsy Devices Market Segmentation

IMARC Group provides an analysis of the key trends in each segment of the Australia biopsy devices market, along with forecasts at the country and regional levels from 2026-2034. The market has been categorized based on procedure type, product, guidance technique, application, end user, and region.

By Procedure Type:

• Surgical Biopsy

• Needle Biopsy

By Product:

• Biopsy Guidance Systems

• Needle Based Biopsy Guns

• Biopsy Needles

• Biopsy Forceps

• Others

By Guidance Technique:

• Ultrasound Guided Biopsy

• Stereotactic Guided Biopsy

• MRI Guided Biopsy

• Others

By Application:

• Breast Biopsy

• Lung Biopsy

• Colorectal Biopsy

• Prostate Biopsy

• Others

By End User:

• Hospitals and Clinics

• Academic and Research Institutes

• Others

By Region:

• Australia Capital Territory & New South Wales

• Victoria & Tasmania

• Queensland

• Northern Territory & Southern Australia

• Western Australia

Key Players in the Australia Biopsy Devices Market

The competitive landscape of the Australia biopsy devices market features a mix of global medtech leaders and innovative Australian companies driving diagnostic technology forward. Major international players including BD (Becton, Dickinson and Company), Hologic Inc., Medtronic, Boston Scientific Corporation, and Intuitive Surgical maintain strong market positions through comprehensive product portfolios spanning biopsy needles, guidance systems, and robotic platforms. Australian innovators are making notable contributions, with Optiscan Imaging advancing optical biopsy and AI-powered endoscopy technology in partnership with Monash University, and La Trobe University developing breakthrough liquid biopsy diagnostics for esophageal cancer. Body Vision Medical's LungVision platform gained TGA approval in 2025, while the Ion robotic bronchoscope from Intuitive Surgical was deployed at Epworth Eastern. Competition is shaped by clinical evidence demonstrating improved diagnostic yields, TGA regulatory clearance, integration with existing hospital imaging infrastructure, and the ability to support precision oncology workflows.

Key Aspects Required for the Australia Biopsy Devices Market Report

• Market Performance: An in-depth analysis of the Australia biopsy devices market covering historical trends and current dynamics, with a focus on the USD 59.1 Million valuation and projected growth trajectory reaching USD 94.3 Million by 2034.

• Market Segmentation: Comprehensive breakdown across procedure types (surgical, needle), products (guidance systems, biopsy guns, needles, forceps), guidance techniques (ultrasound, stereotactic, MRI), applications (breast, lung, colorectal, prostate), and end users.

• Regional Analysis: Detailed evaluation of biopsy device demand across ACT & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia, covering cancer center distribution and diagnostic infrastructure.

• Competitive Landscape: Profiling of major players including BD, Hologic, Medtronic, Boston Scientific, and Australian innovators like Optiscan Imaging, covering product portfolios, technology platforms, and clinical adoption patterns.

• Industry Trends and Drivers: Assessment of rising cancer incidence, national screening program expansion, AI-powered navigation systems, robotic biopsy platforms, liquid biopsy emergence, and precision oncology investment driving market growth.

• Technology Analysis: Examination of image-guided biopsy systems (ultrasound, MRI, stereotactic), AI-assisted diagnostics, robotic bronchoscopy, optical biopsy, telepathology, and liquid biopsy innovations transforming the Australian diagnostic landscape.

• Regulatory and Funding Analysis: Evaluation of TGA device approval pathways, MBS reimbursement frameworks, federal healthcare budget allocations, and precision oncology funding programs supporting biopsy device procurement and adoption.

• Future Outlook: Forward-looking projections covering the implications of the National Lung Cancer Screening Programme, robotic platform adoption, AI integration, liquid biopsy commercialization, and genomic profiling demand on long-term market expansion.

Recent News and Developments

• September 2025: Epworth Eastern in Melbourne became the first private hospital in Australia to deploy the next-generation Ion robotic bronchoscope, achieving diagnostic yields up to 90% for challenging pulmonary nodules and transforming lung cancer diagnosis pathways.

• July 2025: Australia launched the National Lung Cancer Screening Programme (NLCSP) using low-dose CT scans to screen high-risk individuals aged 50 to 70 with significant smoking histories, driving increased demand for confirmatory lung biopsy procedures.

• March 2025: Body Vision Medical's LungVision AI-driven imaging system received TGA regulatory approval, enabling real-time 3D navigation during bronchoscopic biopsies by transforming standard C-arm fluoroscopy into an advanced imaging platform.

• 2025: The federal budget allocated AUD 150.3 million to extend precision oncology programs including the Zero Childhood Cancer Program, the Precision Oncology Screening Platform (PrOSPeCT), and the Australian Rare Cancers Portal.

• 2025: NSW implemented AI-driven machine reading technology in breast screening programs, projected to reduce the number of women recalled for additional diagnostic procedures including needle biopsies by approximately 20%.

• November 2024: Optiscan Imaging partnered with Monash University to develop AI-powered endoscopes for real-time cancer detection during gastrointestinal procedures, supported by an Australian government CRC-P grant.

• October 2024: La Trobe University announced a breakthrough in developing a liquid biopsy test for esophageal cancer, offering enhanced diagnostic precision and reduced dependence on invasive tissue sampling procedures.

• April 2024: Optiscan Imaging was featured as a leader of optical biopsy innovation in Australia through a new device for breast surgery and a telepathology platform aimed at improving real-time cancer diagnosis and surgical accuracy.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=33378&flag=C

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 611 7970
United States: +1-631-791-1145

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a great impact. The company provides a comprehensive suite of market entry and expansion services. IMARC's offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, and networking facilitation, among others.

The company has done projects in over 135 countries and has helped more than 2,500 clients across the globe. IMARC currently works from 11 offices across the world, including its headquarters in Noida, India. It has a team of over 600 people, including former industry executives, subject matter experts, and management professionals. IMARC is among the top 10 management consulting firms based in India.

This release was published on openPR.